FDA green lights first-ever RSV vaccine for adults 60+

The following is an excerpt from Medpage Today. The FDA has approved the first-ever vaccine for respiratory syncytial virus (RSV) the agency announced on Wednesday. Marketed under the trade name of Arexvy, the adjuvanted RSV prefusion F protein-based vaccine is specifically indicated for preventing lower respiratory tract infections in adults 60 and over. Until now, no […]

Share DeepPol